Skip to main content

Table 4 Therapy and mortality of patients with Pseudomonas aeruginosa producing metallo-β-lactamase hospital-acquired pneumonia

From: Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study

Treatment

Hospital-acquired pneumonia (n = 42)

Ventilator-associated pneumonia (n = 22)

 

Treated patients

30-day mortality (n = 24)

Treated patients

30-day mortality (n = 17)

Appropriate monotherapy

18 (42.9)

9 (50.0)

12 (54.5)

9 (75.0)

   Aztreonama

8

2

3

2

   Polymyxin Bb

6

4

5

4

   Piperacillin-tazobactamc

4

3

4

3

Appropriate combination therapy

3 (7.1)

0 (0.0)

1 (4.5)

0 (0.0)

   Polymyxin B + aztreonam

2

0

1

0

   Aztreonam + amikacin

1

0

-

-

Nonappropriate combination therapy

3 (7.1)

2 (66.7)

1 (4.5)

0

   Aztreonam + ceftazidime + amikacin

1

1

-

-

   Imipenem + ceftazidime

1

0

1

0

   Imipenem + ciprofloxacin

1

1

-

-

Nonappropriate monotherapy

17 (40.5)

12 (70.6)

8 (36.4)

8 (100)

   Cefepime

7

5

3

3

   Meropenem

6

3

2

2

   Imipenem

2

2

2

2

   Ceftazidime

1

1

1

1

   Amikacin

1

1

-

-

Without therapy

1 (2.4)

1 (100)

-

-

  1. aThe association of in vitro nonsusceptible antibiotics were used in three patients: ceftazidime (one patient), cefepime (one patient), and ceftazidime + amikacin (one patient); all were survivors. bOne patient received the association of cefepime (in vitro nonsusceptible); survivor. cOne patient received the association of ciprofloxacin (in vitro nonsusceptible); nonsurvivor.
Back to article page

Critical Care

ISSN: 1364-8535